Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 15, 2025CancersOpen Access

Drivers of Pancreatic Cancer: Beyond the Big 4

View Full Paper
Ask AI
Bookmark
Share

Authors

LPLaura PorczaRBRafael Ballesteros-CilleroLLLok To Lam

Discussion

Loading...

Member takes

Overview

Review identifies loss of PTEN and other proteins as significant in PDAC, suggesting new therapeutic targets.

Key Points

  • MAIN FINDING: The review emphasizes the role of non-genetic factors in pancreatic cancer, particularly PTEN loss.
  • KEY EVIDENCE: More than half of PDAC cases show loss of PTEN protein despite low genetic mutation rates.
  • APPROACH: The analysis includes immunohistochemical studies examining protein expression in PDAC cases.
  • SIGNIFICANCE: Understanding these pathways opens new avenues for treatment strategies beyond traditional targets.

Cite This Study

Porcza et al. (2025) studied this question.

synapsesocial.com/papers/689a02bce6551bb0af8cc8a0https://doi.org/10.3390/cancers17142354
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1KRAS: the Achilles’ heel of pancreas cancer biology2025 · 46 citations
  2. 2Targeting Advanced Pancreatic Ductal Adenocarcinoma: A Practical Overview2025
  3. 3Tumour genotype shapes blood biomarker expression for use in pancreatic cancer detection and diagnosis.2025
  4. 4Contemporary insights into the molecular mechanisms of development and genetic susceptibility to pancreatic cancer2025
  5. 5Molecular Pathology of Pancreatic Ductal Adenocarcinoma2025